Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05376189
Other study ID # 0204221709
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date July 1, 2022
Est. completion date February 1, 2023

Study information

Verified date May 2022
Source Hasanuddin University
Contact Jainal Arifin, MD
Phone +6281144422666
Email ia.jenal@yahoo.co.id
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background : The toll-like receptor is an essential receptor that stimulates the innate immunity response. In tuberculosis, toll-like receptors, particularly the TLR-2, and TLR-4 are crucial in recognizing various ligands with a lipoprotein structure in the bacilli. Vitamin D deficiency leads to lower expression of these receptors, Hence the immune response against Mycobacterium tuberculosis will be altered. Various studies addressed the importance of vitamin D supplementation in pulmonary tuberculosis but the effect of vitamin D in extrapulmonary tuberculosis, particularly spondylitis tuberculosis is not sufficiently identified. Objectives: To assess the effect of oral vitamin D supplementation on the expression of TLR-2, TLR-4, and clinical outcomes in spondylitis tuberculosis patients. Methodology: This study proposes a randomized clinical trial of oral vitamin D supplementation in spondylitis tuberculosis patients. Multiple arms will be established with different doses and control groups. The outcome of interest includes the clinical outcomes, the expression of TLR-2, and TLR 4 Hypothesis : It is assumed that oral supplementation of Vitamin D will increase the activation of Toll-Like Receptors and improves the clinical condition of Spondylitis Tuberculosis patients


Description:

Target population: Patients with spondylitis tuberculosis without the involvement of lung and other extrapulmonary infection Design: Randomized Clinical Trial with 3 arms Primary Intervention: Standardized Tuberculosis treatment with oral Vitamin D3 Supplementation daily for 8 weeks Outcome: 1. Toll-Like Receptors (TLR) 2 and 4 levels from the blood sample, measured using Enzyme-linked Immunoassay (ELISA). 2. Clinical Evaluation with Visual Analogue Scale (VAS) and Oswestry Disability Index (ODI). The outcomes will be measured three times at 4-week intervals (baseline, week 4, and week 8) Sample Size and Recruitment Participants will be recruited from hospitals and allocated by simple randomization Biological Sample and consent 1. Participants are aware that clinical data collection and biological samples will be obtained by researchers. This is mentioned in informed consent prior to study recruitment 2. Blood sample will be obtained in a standardized phlebotomy procedure and will not be retained after the study is finish. Hypothesis Sample Size Calculation: The trial will be designed to compare 2 experimental treatments to a shared control arm. The sample size was estimated based on the mathematical calculation by a study below Grayling, M.J et al With the assumption of : 1. K=2 experimental treatments will be included in the trial. 2. A significance level of α=0.05 will be used, in combination with no multiple comparison correction. 3. The event rate in the control arm will be assumed to be: λ0=5. 4. The marginal power for each null hypothesis will be controlled to level 1-β=0.8 under each of their respective least favorable configurations. 5. The interesting and uninteresting treatment effects will be δ1=2.5 and δ0=0 respectively. 6. The target allocation to each of the experimental arms will be the same as the control arm. 7. The sample size in each arm will not be required to be an integer. Hence total sample should be 37 participants Proposed Statistical Analysis 1. Descriptive Statistics 2. Bivariate Analysis 3. The study will apply intention-to-treat analysis 4. Linear Mixed model to measure the effect of intervention adjusted by fixed and random factors.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 37
Est. completion date February 1, 2023
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 19 Years to 50 Years
Eligibility Inclusion Criteria: 1. Diagnosed as Spondylitis Tuberculosis (Clinically and Laboratory confirmed) 2. Level of Total Vitamin D <50 nmol/L at baseline Exclusion Criteria: 1. Participants with pulmonary tuberculosis or other extrapulmonary tuberculosis 2. Participants with osteoporosis, malignancy, cardiovascular disease, diabetes mellitus, and autoimmune disease 3. Participants with liver and kidney dysfunction 4. Participants who received Vitamin D prior to enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
400 IU
An Oral Vitamin D3 400 IU will be given once daily for a total of 8 weeks
5000 IU
An Oral Vitamin D3 5000 IU will be given once daily for a total of 8 weeks
10000 IU
An Oral Vitamin D3 10000 IU will be given once daily for a total of 8 weeks
Drug:
Fixed Drug Combination
Standard Tuberculosis Regimen in a form of Fixed Drug Combination (FDC) given for Spondylitis Tuberculosis.

Locations

Country Name City State
Indonesia Wahidin Sudirohusodo General Hospital Makassar South Sulawesi

Sponsors (1)

Lead Sponsor Collaborator
Hasanuddin University

Country where clinical trial is conducted

Indonesia, 

References & Publications (5)

Grayling MJ, Wason JM. A web application for the design of multi-arm clinical trials. BMC Cancer. 2020 Jan 31;20(1):80. doi: 10.1186/s12885-020-6525-0. — View Citation

Ojaimi S, Skinner NA, Strauss BJ, Sundararajan V, Woolley I, Visvanathan K. Vitamin D deficiency impacts on expression of toll-like receptor-2 and cytokine profile: a pilot study. J Transl Med. 2013 Jul 22;11:176. doi: 10.1186/1479-5876-11-176. — View Citation

Panwar A, Garg RK, Malhotra HS, Jain A, Singh AK, Prakash S, Kumar N, Garg R, Mahdi AA, Verma R, Sharma PK. 25-Hydroxy Vitamin D, Vitamin D Receptor and Toll-like Receptor 2 Polymorphisms in Spinal Tuberculosis: A Case-Control Study. Medicine (Baltimore). 2016 Apr;95(17):e3418. doi: 10.1097/MD.0000000000003418. — View Citation

Tang L, Liu S, Bao YC, Gao RX, Han CF, Sun XC, Zhang WL, Feng SQ. Study on the relationship between vitamin D deficiency and susceptibility to spinal tuberculosis. Int J Surg. 2017 Aug;44:99-103. doi: 10.1016/j.ijsu.2017.05.077. Epub 2017 Jun 16. — View Citation

Yu, Fang & Cailiang, Shen. (2019). Effect of vitamin D combined with anti-tuberculosis drugs on serum IL-1ß, IFN-? and TH17 cell-associated cytokines for the management of spinal tuberculosis. Tropical Journal of Pharmaceutical Research. 18. 1141-1147. 10.4314/tjpr.v18i5.32.

Outcome

Type Measure Description Time frame Safety issue
Primary The Oswestry Disability Index This questionnaire assess the impact of back pain to the daily life. This questionnaire contains 10 6-likert scale questions with the score ranging from 0-5 for each questions. The total score ranging from 0-50. The index is calculated as raw score per total score and presented as percentage. Below is the classification and interpretation of the score:
0% -20%: Minimal disability 21%-40%: Moderate Disability 41%-60%: Severe Disability 61%-80%: Crippling back pain 81%-100%: These patients are either bed-bound or have an exaggeration of their symptoms
Changes of Score from Baseline to 8 weeks
Primary The Visual Analogue Scale This scale represent the pain according to a visual score measured using 10-likert scale. Maximum number indicates extreme/intractable pain Changes of Score from Baseline to 8 weeks
Primary Toll-Like Receptor 2 (TLR-2) The level of TLR-2 in blood measured using ELISA Changes of TLR-2 level from Baseline to 8 weeks
Primary Toll-Like Receptor 4 (TLR-2) The level of TLR-4 in blood measured using ELISA Changes of TLR-4 level from Baseline to 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2